Vaso AI Stock Analysis
Want to see VASO full AI Analyst Report?
Vaso (VASO) AI Stock Analysis
Vaso
(Other OTC:VASO)
Vaso's overall score of 72 is primarily driven by its exceptional balance sheet stability and robust technical momentum. While fair valuation and proactive board appointments add to its appeal, management must address recent revenue contractions to unlock further potential.
Vaso (VASO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $49.80M
- Dividend Yield
- ―
- Average Volume (3M)
- 130.18K
- Price to Earnings (P/E)
- 17.3
- Beta (1Y)
- 0.63
- Revenue Growth
- -8.03%
- EPS Growth
- ―
- Country
- US
- Employees
- 282
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Vaso Business Overview & Revenue Model
Company Description
Vaso Corporation is a diversified enterprise engaged in both the healthcare equipment and information technology industries, serving markets within the United States and globally. The company's operations are structured across three primary divisions...
Vaso Financial Statement Overview
Summary
Vaso demonstrates a solid financial foundation driven by a pristine balance sheet and exceptional free cash flow. These strengths help offset recent top-line revenue contraction and pressured operating margins.
Income Statement
42NeutralBalance Sheet
88Very PositiveCash Flow
78Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 80.22M | 89.10M | 86.77M | 81.02M | 80.02M | 75.58M |
| Gross Profit | 51.98M | 54.67M | 52.05M | 50.59M | 48.48M | 43.13M |
| EBITDA | 413.00K | -423.00K | 2.10M | 5.95M | 8.38M | 6.66M |
| Net Income | 2.79M | 1.57M | 951.00K | 4.80M | 11.87M | 6.10M |
Balance Sheet | ||||||
| Total Assets | 85.91M | 88.35M | 82.94M | 75.76M | 72.66M | 52.36M |
| Cash, Cash Equivalents and Short-Term Investments | 38.29M | 35.05M | 26.27M | 25.32M | 20.32M | 6.65M |
| Total Debt | 1.79M | 1.81M | 2.38M | 2.06M | 1.80M | 1.39M |
| Total Liabilities | 56.70M | 58.92M | 55.24M | 48.91M | 49.78M | 41.05M |
| Stockholders Equity | 29.21M | 29.43M | 27.70M | 26.84M | 22.88M | 11.31M |
Cash Flow | ||||||
| Free Cash Flow | 6.90M | 8.35M | 1.83M | 4.57M | 13.85M | 7.40M |
| Operating Cash Flow | 7.86M | 9.27M | 3.28M | 5.30M | 14.42M | 7.82M |
| Investing Cash Flow | -821.00K | -725.00K | 11.73M | -5.66M | -8.42M | -260.00K |
| Financing Cash Flow | -834.00K | 248.00K | -89.00K | -134.00K | -230.00K | -8.33M |
Vaso Risk Analysis
Vaso disclosed 32 risk factors in its most recent earnings report. Vaso reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksVaso Peers Comparison
Overall Rating
VASO72Outperform
BEAT43Neutral
VSEE42Neutral
HCTI38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | $49.80M | 17.28 | 9.68% | ― | -8.03% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | $25.04M | -0.94 | -402.72% | ― | ― | 38.22% | |
| 42Neutral | $266.01K | -0.01 | -400.87% | ― | -9.31% | 89.42% | |
| 38Underperform | $3.24M | -0.00 | -43.51% | ― | 141.89% | 99.35% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VASO | Vaso Corp | 0.28 | 0.14 | 101.43% | |
| HCTI | Healthcare Triangle, Inc. | 3.66 | -2228.34 | -99.84% | |
| BEAT | Heartbeam, Inc. | 0.40 | -1.15 | -74.35% | |
| VSEE | Vsee Health, Inc. | 0.33 | -55.75 | -99.41% | |
| BFRG | BullFrog AI Holdings, Inc. | 0.54 | -0.38 | -41.20% | |
| MGRX | Mangoceuticals, Inc. | 0.15 | -1.10 | -87.70% |
Vaso Corporate Events
Vaso Completes Sale of NetWolves Network Services
NeutralOn July 31, 2026, Vaso Corporation and its subsidiary VasoTechnology, Inc. completed the sale of all issued and outstanding membership interests in NetWolves Network Services LLC to COEO Solutions, LLC under an Equity Purchase Agreement. The cash bas...
Vaso Adds Financial Expert Shaun McMeans to Board
PositiveOn July 23, 2026, Vaso Corporation appointed 64-year-old finance executive Shaun McMeans as a Class III director and member of its audit committee, effective immediately. The move adds a designated financial expert to the board, reinforcing governanc...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 20, 2026
